Andreas M. Zeiher
Goethe University Frankfurt
606 Papers
7.5K Citations
Andreas M. Zeiher is an academic researcher from Goethe University Frankfurt. The author has contributed to research in topics: Medicine & Myocardial infarction. The author has an hindex of 129, co-authored 571 publications. Previous affiliations of Andreas M. Zeiher include University of Hamburg.
Chat about Author
Papers
Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML
Anjali Cremer,Julius C. Enßle,Saskia Pfaff,Khouloud Kouidri,Fabian Lang,Christian Brandts,Andreas M. Zeiher,Sebastian Cremer,Björn Steffen,Hubert Serve,Gesine Bug +10 more
TL;DR: Treatment with midostaurin and/or FLT3i is identified as an independent risk factor for CAEs not resulting in higher non-relapse mortality (NRM) or impaired overall survival (OS) and close monitoring for CAEs is warranted for these patients.
2
Kommentar zu den Leitlinien (2018) der ESC und EACTS zur Myokardrevaskularisation
Franz-Josef Neumann,Robert A. Byrne,Dirk Sibbing,Adnan Kastrati,Norbert Frey,T. Doenst,Jan Gummert,Andreas M. Zeiher,Volkmar Falk +8 more
- 17 Jul 2019
TL;DR: The guidelines are intended to support the treatment of patients with coronary artery disease by pragmatic evidence-based recommendations.
2
•Journal Article
Abstract 16492: MiR-92a Controls Metabolism and Obesity
Daniela Penzkofer,Timon Seeger,Angelika Bonauer,Ariane Fischer,Andreas M. Zeiher,Stefanie Dimmeler +5 more
TL;DR: A large number of patients with obesity and type 2 diabetes are at risk for coronary artery disease, and microRNAs, which act as negative regulators of gene expres...
2
•Journal Article
Abstract 3688: Predictors of Contractile Recovery of Left Ventricular Function After Intracoronary Infusion of Bone-Marrow-Derived Progenitor Cells in Patients with Acute Myocardial Infarction: Lessons from the REPAIR-AMI Trial
Volker Schächinger,Sandra Erbs,Albrecht Elsässer,Werner Haberbosch,Rainer Hambrecht,Hans Hölschermann,Jiangtao Yu,Roberto Corti,Detlef G. Mathey,Christian W. Hamm,Tim Suselbeck,Birgit Assmus,Torsten Tonn,Stefanie Dimmeler,Andreas M. Zeiher +14 more
2
Use of high-intensity statin therapy post-acute coronary syndrome in the ongoing odyssey outcomes trial of alirocumab, a proprotein convertase subtilisin/kexin type 9 monoclonal antibody, versus placebo: interim baseline data
Shaun G. Goodman,Gregory G. Schwartz,Deepak L. Bhatt,Vera Bittner,Rafael Diaz,Corinne Hanotin,Robert A. Harrington,Johan Wouter Jukema,Angele Moryusef,Robert Pordy,Matthew T. Roe,William J. Sasiela,Michael Szarek,Jean-Francois Tamby,Harvey D. White,Andreas M. Zeiher +15 more
TL;DR: The ODYSSEY OUTCOMES trial tests the hypothesis that alirocumab, a fully human drug, can treat acute coronary syndromes with low-density lipoprotein cholesterol levels.
2